Coverage
-
February 20, 2013
Teva Pharmaceuticals USA Inc. has agreed to a settlement with Gilead Sciences Inc. to end a patent infringement dispute over its planned generic version of antiviral treatment Viread, heading off a trial that was set to begin Wednesday in New York federal court, Gilead said Tuesday.
1 other articles on this case.
View all »